Trump Signs Executive Order to Accelerate Research on Psychedelic Drugs

On April 18, 2026, President Donald Trump signed an executive order in the Oval Office aimed at expediting research and access to psychedelic drugs, including ibogaine, for treating post-traumatic stress disorder (PTSD) among veterans. This landmark move is seen as a potential game-changer in how the U.S. approaches mental health treatments, particularly for military personnel suffering from debilitating conditions.

During the signing ceremony, Trump emphasized the urgency of addressing the mental health crisis facing veterans, stating, "Today’s order will help people suffering from debilitating symptoms reclaim their lives and lead happier lives." He pointed out that since the September 11 attacks, more than 21 times as many veterans have died by suicide compared to those lost in combat, calling the situation a "national tragedy."

Accompanied by U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and several military veterans, including former Navy SEAL Marcus Luttrell, Trump announced the allocation of $50 million for federal research into ibogaine. This funding aims to support state-level initiatives and open pathways for its use under the Right to Try law, which allows terminally ill patients to access experimental treatments.

Ibogaine, a substance derived from an African shrub, has shown promise in treating various mental health disorders, including PTSD, anxiety, and depression. During the event, Luttrell shared his personal experience with ibogaine, stating, "It absolutely changed my life for the beter." He expressed hope that the executive order would lead to broader access to this potentially life-saving treatment for veterans.

Trump's order directs the U.S. Food and Drug Administration (FDA) to issue new guidance for conducting clinical trials on psychedelics and to facilitate the fast-tracking of any FDA-approved psychedelic drugs. The FDA has previously granted "breakthrough therapy" designation to some psychedelics, indicating that they may provide substantial improvement over existing therapies. This designation allows for expedited review processes, which could see treatments available to patients much sooner than typical timelines.

Health Secretary Kennedy echoed the president’s sentiments, stating, "We’re taking this decisive step to confront one of the most urgent public health challenges facing our nation, the mental health crisis." He noted that the executive order would remove legal impediments that have historically blocked researchers and health professionals from studying the therapeutic potential of psychedelics.

In addition to ibogaine, the executive order encompasses other psychedelics such as psilocybin, LSD, and MDMA, which have been researched for their therapeutic effects. According to Trump, these experimental treatments have demonstrated life-changing potential for individuals suffering from severe mental illnesses. He remarked, "If these turn out to be as good as people are saying, it's going to have a tremendous impact on this country and other countries too."

The initiative has received bipartisan support, with lawmakers pledging to pursue legislation that expands access to psychedelic therapies. Rep. Morgan Luttrell, who attended the signing, stated, "We will continue working in Congress to build on the president's leadership and expand access to this life-saving treatment." This commitment reflects a growing acknowledgment of the need for innovative approaches to mental health care, especially for veterans.

Critics, meanwhile, have raised concerns about the potential risks associated with accelerating the approval process for psychedelic treatments. Some experts warn that ibogaine, in particularly, has been linked to serious side effects, including cardiovascular issues. Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, noted the challenges of studying ibogaine due to its known cardiotoxicity. He stated, "If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a superior psychedelic therapy compared to others."

The executive order comes on the heels of Trump’s previous initiatives to reform drug policy, including an order in December 2025 that aimed at reclassifying marijuana. The recent focus on psychedelics marks a shift in federal policy, as the government seeks to explore alternatives to traditional mental health treatments, which have been criticized for their ineffectiveness in some cases.

As the administration moves forward, FDA Commissioner Marty Makary announced that his agency would issue three national priority vouchers for psychedelics, expediting the approval process for drugs aligned with national health priorities. This could potentially lead to the first human trials for ibogaine in the United States, a milestone eagerly anticipated by advocates of psychedelic therapy.

Supporters of the initiative argue that psychedelics could offer long-lasting relief for millions of Americans suffering from mental health disorders. A 2024 Stanford University study indicated that ibogaine could significantly reduce symptoms of depression and anxiety among veterans, with participants experiencing an 80% to 90% reduction in symptoms within a month of treatment. Such findings have fueled growing interest in the therapeutic applications of psychedelics.

In the aftermath of this executive order, many are hopeful that the U.S. will take meaningful steps toward integrating psychedelic therapies into mainstream mental health care. As research progresses, the potential for these substances to transform treatment options for veterans and others suffering from mental health issues is becoming increasingly tangible. The administration's commitment to exploring these avenues reflects a broader societal shift toward acknowledging the potential benefits of psychedelics in addressing mental health crises.

Looking ahead, the FDA is expected to act swiftly on applications for psychedelic treatments, with the possibility of government-sanctioned therapies beginning as early as this summer. As Trump concluded during the signing ceremony, "We’re bringing them new hope." This new direction could mark a historic moment in the fight against the mental health crisis affecting countless Americans.